Effects of paroxetine on cardiovascular response to mental stress in subjects with a history of coronary artery disease and no psychiatric diagnoses

Psychopharmacology

Volumn 182, Issue 3, 2005, Pages 321-326

  Golding, Michael ^a,b,g   Kotlyar, Michael ^c,d   Carson, Stanley W ^b,e   Hoyler, Sherri ^e   Lazarus, Cindy ^b   Davidson, Colin ^f   Guzzo, Joseph ^b   Sontz, Eric ^b   Garbutt, J C ^b  

^a Psych Support Inc   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

^e UNIVERSITY OF NORTH CAROLINA   (United States)

^f DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g Physch Support Inc   (United States)

Author keywords

Cardioprotection; Coronary disease; Depression; Hypertension; Mental stress; Paroxetine; Reactivity; SSRI

Indexed keywords

NORADRENALIN; PAROXETINE;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RESPONSE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; FEMALE; HEART PROTECTION; HEART RATE; HUMAN; MALE; MENTAL STRESS; NORADRENALIN BLOOD LEVEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE;

AGED; BLOOD PRESSURE; CORONARY DISEASE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; NOREPINEPHRINE; PAROXETINE; PULSE; STRESS, PSYCHOLOGICAL;

EID: 26844535407     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-005-0075-7     Document Type: Article

References (25)

1. Alvarez W Jr, Pickworth KK (2003) Safety of antidepressant drugs in the patient with cardiac disease: a review of the literature. Pharmacotherapy 23:754-771
2. Amsterdam JD, Garcia-Espana F, Fawcett J, Quitkin FM, Reimherr FW, Rosenbaum JF, Beasley C (1999) Blood pressure changes during short-term fluoxetine treatment. J Clin Psychopharmacol 19:9-14
3. Antonaccio MJ, Robson RD (1973) Cardiovascular effects of 5-hydroxytryptophan in anaesthetized dogs. J Pharm Pharmacol 25:495-497
4. Blatt CM, Rabinowitz SH, Lown B (1979) Central serotonergic agents raise the repetitive extrasystole threshold of the vulnerable period of the canine ventricular myocardium. Circ Res 44:723-730
5. Blumenthal JA, Jiang W, Waugh RA, Frid DJ, Morris JJ, Coleman RE, Hanson M, Babyak M, Thyrum ET, Krantz DS et al (1995) Mental stress-induced ischemia in the laboratory and ambulatory ischemia during daily life. Association and hemodynamic features. Circulation 92:2102-2108
6. Davidson JR, Potts NL, Richichi EA, Ford SM, Krishnan KR, Smith RD, Wilson W (1991) The brief social phobia scale. J Clin Psychiatr 52(Suppl):48-51
7. DeVane CL, Ware MR, Emmanuel NP, Brawman-Mintzer O, Morton WA, Villarreal G, Lydiard RB (1999) Evaluation of the efficacy, safety and physiological effects of fluvoxamine in social phobia. Int Clin Psychopharmacol 14:345-351
8. Flockhart DA, Tanus-Santos JE (2002) Implications of cytochrome P450 interactions when prescribing medication for hypertension. Arch Intern Med 162:405-412
9. Glassman AH, O'Connor CM, Califf RM, Swedberg K, Schwartz P, Bigger JT Jr, Krishnan KR, van Zyl LT, Swenson JR, Finkel MS, Landau C, Shapiro PA, Pepine CJ, Mardekian J, Harrison WM, Barton D, McLvor M (2002) Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA 288:701-709
10. Goldberg AD, Becker LC, Bonsall R, Cohen JD, Ketterer MW, Kaufman PG, Krantz DS, Light KC, McMahon RP, Noreuil T, Pepine CJ, Raczynski J, Stone PH, Strother D, Taylor H, Sheps DS (1996) Ischemic, hemodynamic, and neurohormonal responses to mental and exercise stress. Experience from the Psychophysiological Investigations of Myocardial Ischemia study (PIMI). Circulation 94:2402-2409
11. Greenblatt DJ, von Moltke LL, Harmatz JS, Shader RI (1999) Human cytochromes and some newer antidepressants: kinetics, metabolism, and drug interactions. J Clin Psychopharmacol 19:23S-35S
12. Hamilton M (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56-62
13. Jiang W, Babyak M, Krantz DS, Waugh RA, Coleman RE, Hanson MM, Frid DJ, McNulty S, Morris JJ, O'Connor CM, Blumenthal JA (1996) Mental stress-induced myocardial ischemia and cardiac events. JAMA 275:1651-1656
14. Kirschbaum C, Pirke KM, Hellhammer DH (1993) The 'Trier Social Stress Test' - a tool for investigating psychobiological stress responses in a laboratory setting. Neuropsychobiology 28:76-81
15. Krantz DS, Santiago HT, Kop WJ, Bairey Merz CN, Rozanski A, Gottdiener JS (1999) Prognostic value of mental stress testing in coronary artery disease. Am J Cardiol 84:1292-1297
16. Manuck SB, Olsson G, Hjemdahl P, Rehnqvist N (1992) Does cardiovascular reactivity to mental stress have prognostic value in postinfarction patients? A pilot study. Psychosom Med 54:102-108
17. Marais GE, Verrier RL, Lown B (1981) Mechanisms mediating the protective effects of central serotonergic agonists on vulnerability to ventricular fibrillation in the normal and ischemic heart (abstract). Circulation 64:320
18. Masand PS, Gupta S (1999) Selective serotonin-reuptake inhibitors: an update. Harv Rev Psychiatry 7:69-84
19. Rabinowitz SH, Lown B (1978) Central neurochemical factors related to serotonin metabolism and cardiac ventricular vulnerability for repetitive electrical activity. Am J Cardiol 41:516-522
20. Sheps DS, McMahon RP, Becker L, Carney RM, Freedland KE, Cohen JD, Sheffield D, Goldberg AD, Ketterer MW, Pepine CJ, Raczynski JM, Light K, Krantz DS, Stone PH, Knatterud GL, Kaufmann PG (2002) Mental stress-induced ischemia and all-cause mortality in patients with coronary artery disease: results from the Psychophysiological Investigations of Myocardial Ischemia study. Circulation 105:1780-1784
21. Straneva P, Schwartz S, Gibson D, Golding M, Lee R, Girdler S (2001) Effects of two classes of antidepressant medications on cardiovascular reactivity to laboratory stress (abstract). Psychosom Med 63:144-145
22. Straneva-Meuse PA, Light KC, Allen MT, Golding M, Girdler SS (2004) Bupropion and paroxetine differentially influence cardiovascular and neuroendocrine responses to stress in depressed patients. J Affect Disord 79:51-61
23. Strike PC, Steptoe A (2003) Systematic review of mental stress-induced myocardial ischaemia. Eur Heart J 24:690-703
24. Tucker P, Smith KL, Marx B, Jones D, Miranda R, Lensgraf J (2000) Fluvoxamine reduces physiologic reactivity to trauma scripts in posttraumatic stress disorder. J Clin Psychopharmacol 20:367-372
25. Verrier RL (1986) Neurochemical approaches to the prevention of ventricular fibrillation. Fed Proc 45:2191-2196